+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Immunosuppressive Drug Market Research and Forecast 2018-2023

  • ID: 4700795
  • Report
  • October 2018
  • Region: Global
  • Orion Market Research Private Limited
until Mar 31st 2020
1 of 3


  • Abbvie, Inc.
  • Apitope
  • Bioagilytix Labs
  • F. Hoffmann-La Roche Ltd.
  • Globela Pharma Pvt. Ltd.
  • Novartis Ag
  • MORE
Immunosuppressive drugs are used for the treatment of end-stage organ replacement or failure. These drugs are anti-rejection drugs used to make the body less likely to reject a transplanted organ, such as a liver, heart, or kidney. Increasing incidence of chronic ailments and the demand for organ replacement is expected to drive the growth of the market. In addition, growing adoption of tissues engineering in organ transplant also significantly contributing to the market growth. However, high drug cost and a shortage of organ donor for transplant are major restraining factors which may affect the growth of immunosuppressive drug market. Currently, the adoption of newer medication option such as scleroderma treatment and increased use of tissue engineering, which enable in the generation of organs has brought new opportunity to immunosuppressive drug market.

The market is segmented on the basis of application and drug type. On the basis of application, the market is segmented into bone marrow transplant, heart transplant, kidney transplant, liver transplant, and lungs transplant. Kidney transplant and bone marrow transplant is expected to have a considerable share in the market owing to a rise in kidney failure cases. On the basis of drug type, the market is segmented into antibodies, calcineurin inhibitor, antiproliferative agent, MTOR inhibitors and steroids. Calcineurin inhibitor is expected to have the largest market share among all drug type as it is widely used in solid organ transplantation.

Geographically immunosuppressive drug market is divided into North America, Europe, Asia Pacific and Rest of the World. North America region represents considerably the largest market for the immunosuppressive drug in terms of its uses and revenue generation owing to an increase in the prevalence of chronic disease and rising number of transplant procedure. APAC is expected to be the fastest growing region owing to rising government initiatives to reduce the prices of drugs. For instance, in India, National Pharmaceuticals Pricing Authority (NPPA) decided to slash the prices of immunosuppressive drugs by 50% in 2016. Europe is expected to have a moderative growth in immunosuppressive drug market due to an increase in kidney transplant recipients. The major countries that will contribute to the market are the UK, Germany, Spain, France, Italy.

The global players in the immunosuppressive drug market include AbbVie Inc, Actiza Pharmaceutical, Bristol-Myers Squibb company, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd. The strategy adopted in these companies are continuous development in immunosuppressive solution by (R&D) which made them progress over the past several years. As a result, the market player may offer low-cost, high-value solutions and services for transplant surgery. In April 2018, 4D Molecular Therapeutics (4DMT), expand its 2016 research agreement with F. Hoffmann-La Roche Ltd into a broad long-term strategic partnership to develop and commercialize multiple ophthalmology products.

Research methodology

The market study of global immunosuppressive drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, a country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. Immunosuppressive drug enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Authentic Public Databases such as the kidney.org, organindia.org, cancer.gov and so on.
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalog.
The Report is intended for immunosuppressive drug OEM manufacturers, Investing companies, Government Organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating with delivering insights into the market for better business decisions.

Market Segmentation:
  • Global Immunosuppressive Drug market is segmented on the basis of regional outlook and following segments:
  • Global immunosuppressive drug market research and analysis, by application
  • Global immunosuppressive drug market research and analysis, by drug type
The Report Covers::
  • Comprehensive research methodology of the global immunosuppressive drug market.
  • Immunosuppressive drug report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global immunosuppressive drug market.
  • Insights about market determinants which are stimulating the global immunosuppressive drug market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3


  • Abbvie, Inc.
  • Apitope
  • Bioagilytix Labs
  • F. Hoffmann-La Roche Ltd.
  • Globela Pharma Pvt. Ltd.
  • Novartis Ag
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Definition
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Regulation
2.3.1. United States
2.3.2. European Union
2.3.3. China
2.3.4. India

3. Market Determinant
3.1. Motivators
3.1.1. Growing Incidence of Chronic Diseases Resulting in Organ Failure
3.1.2. Advancement in Organ Transplant & Tissue Engineering
3.1.3. Dominance of Key Market Player
3.1.4. Extensive Clinical Studies And R&D Activities
3.2. Restraint
3.2.1. High Cost of Procedure
3.2.2. Lack of Organs Donors for Transplant
3.3. Opportunity
3.3.1. Newer Medication Option
3.3.2. Increasing Used of Tissue Engineering for Implant Generation

4. Market Segmentation
4.1. Global Immunosuppressive Drug Market, By Application
4.1.1. Bone Marrow Transplant
4.1.2. Heart Transplant
4.1.3. Kidney Transplant
4.1.4. Liver Transplant
4.1.5. Lungs Transplant
4.2. Global Immunosuppressive Drug Market, By Drug Type
4.2.1. Antibodies
4.2.2. Calcineurin Inhibitor
4.2.3. Antiproliferative Agent
4.2.4. Motor Inhibitors
4.2.5. Steroids

5. Competitive Landscape
5.1. Key Strategies
5.2. Key Company Analysis

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Spain
6.2.4. France
6.2.5. Italy
6.2.6. Rest of Europe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of Asia Pacific
6.4. Rest of the World

7. Company Profiles
7.1. AbbVie, Inc.
7.2. Apitope
7.3. Allergan PLC
7.4. Astellas Pharma, Inc.
7.5. BioAgilytix Labs
7.6. Bristol-Myers Squibb
7.7. F. Hoffmann-La Roche Ltd.
7.8. GlaxoSmithKline PLC
7.9. Globela Pharma Pvt. Ltd.
7.10. LGM Pharma
7.11. Novartis AG
7.12. Pfizer, Inc.
7.13. Protalex, Inc.
7.14. Rhizen Pharmaceuticals S.A.
7.15. Sanofi S.A.
7.16. SGPharma
7.17. Taj Pharmaceuticals Ltd
7.18. Topas Therapeutics GmbH
7.19. Veloxis Pharmaceuticals A/S
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • Abbvie, Inc.
  • Apitope
  • Allergan Plc
  • Astellas Pharma, Inc.
  • Bioagilytix Labs
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Globela Pharma Pvt. Ltd.
  • Lgm Pharma
  • Novartis Ag
  • Pfizer, Inc.
  • Protalex, Inc.
  • Rhizen Pharmaceuticals S.A.
  • Sanofi S.A.
  • Sgpharma
  • Taj Pharmaceuticals Ltd
  • Topas Therapeutics Gmbh
  • Veloxis Pharmaceuticals A/S
Note: Product cover images may vary from those shown